Financials data is unavailable for this security.
View more
Year on year Petros Pharmaceuticals Inc had relatively flat revenues (5.99m to 5.82m), though the company grew net income from a loss of 20.04m to a smaller loss of 8.16m. A reduction in the selling, general and administrative costs as a percentage of sales from 203.76% to 159.07% was a component in the net income growth despite flat revenues.
Gross margin | 70.21% |
---|---|
Net profit margin | -171.23% |
Operating margin | -389.61% |
Return on assets | -26.18% |
---|---|
Return on equity | -196.48% |
Return on investment | -39.25% |
More ▼
Cash flow in USDView more
In 2023, Petros Pharmaceuticals Inc increased its cash reserves by 41.49%, or 3.91m. Cash Flow from Financing totalled 11.54m or 198.15% of revenues. In addition the company used 7.63m for operations while cash used for investing totalled .
Cash flow per share | -2.90 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.988 |
---|---|
Tangible book value per share | 0.1769 |
More ▼
Balance sheet in USDView more
Current ratio | 1.40 |
---|---|
Quick ratio | 1.26 |
Total debt/total equity | 0.8311 |
---|---|
Total debt/total capital | 0.4539 |
More ▼